Email Alert RSS
Volume 11 Issue 5
Sep.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(5): 621-625
Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
Citation: Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
shu

Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019

doi: 10.3969/j.issn.1674-9081.2020.05.020

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: SUN Qiang Tel: 86-10-69152700, E-mail: sunqiang@163.com
  • Received Date: 2019-11-18
  • Publish Date: 2020-09-30
    Abstract
  • Whether menopausal hormone therapy (MHT) increases the risk of breast cancer has been controversial. In September 2019, the famous medical journal, the Lancet, published a meta-analysis that has gathered the worldwide evidence of MHT and incidence of breast cancer, showing that in addition to vaginal estrogen, all type of MHTs increased the risk of breast cancer, and the risk increased steadily with the duration of MHT use. The risk was greater for oestrogen-progestagen therapy; the excess risk persisted after the drug was stopped for more than 10 years. Low doses of MHT or natural progesterone do not prevent the risk of breast cancer. This article interprets the meta-analysis and emphasizes that MHT should be taken into account of increasing the risk of breast cancer, and the risks and benefits should be fully evaluated.
    • FullText(HTML)
  • loading
    • References(28)
  • [1] Lindsey A, Freddie Bray T, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108. doi:  10.3322/caac.21262
    [2] Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010[J]. Br J Cancer, 2011, 105:S77-S81. doi:  10.1038/bjc.2011.489
    [3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288:321-333. doi:  10.1001/jama.288.3.321
    [4] Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 289:3243-3253. doi:  10.1001/jama.289.24.3243
    [5] Beral V, Reeves G, Bull D, et al. Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy[J]. J Natl Cancer Inst, 2011, 103:296-305. doi:  10.1093/jnci/djq527
    [6] Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J]. Br J Cancer, 2004, 91:644-650. doi:  10.1038/sj.bjc.6601996
    [7] Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J]. Int J cancer, 2005, 114:448-454. doi:  10.1002/ijc.20710
    [8] Roman M, Sakshaug S, Graff-Iversen S, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway[J]. Int J Cancer, 2016, 138:584-593. doi:  10.1002/ijc.29810
    [9] Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?[J].Br J Cancer, 2016, 115:607-615. doi:  10.1038/bjc.2016.231
    [10] Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015, 1:296-305. doi:  10.1001/jamaoncol.2015.0494
    [11] Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, et al. hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older[J]. Acta Oncol, 2014, 53:752-758. doi:  10.3109/0284186X.2013.878471
    [12] Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment[J]. Breast Cancer Res Treat, 2014, 145:535-543. doi:  10.1007/s10549-014-2934-6
    [13] Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies[J]. Eur J Cancer, 2016, 52:138-154. doi:  10.1016/j.ejca.2015.10.063
    [14] Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis[J]. Lancet Oncol, 2006, 7:910-918. doi:  10.1016/S1470-2045(06)70911-1
    [15] Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials[J]. Hum Reprod Update, 2005, 11:561-573. doi:  10.1093/humupd/dmi031
    [16] Manson JE, Chlebowski RT, Stefanick ML, et al. The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases[J]. JAMA, 2013, 301:1353-1368. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011
    [17] Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women[J].N Engl J Med, 2008, 14, 359: 697-708. doi:  10.1097/01.ogx.0000338097.79940.0c
    [18] Chlebowski RT, Anderson GL, Aragaki AK, et al.Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index[J]. J Nat Cancer Inst, 2016;108. http://www.ncbi.nlm.nih.gov/pubmed/26546117
    [19] Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394:1159-1168. doi:  10.1016/S0140-6736(19)31709-X
    [20] Munsell MF, Sprague BL, Berry DA, et al. Body Mass Index and Breast Cancer Risk According to Postmenopausal Estrogen- Progestin Use and Hormone Receptor Status[J]. Epidemiol Rev, 2014, 36:114-136. doi:  10.1093/epirev/mxt010
    [21] Wang K, Li F, Chen L, et al.Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies[J].Oncotarget, 2017, 8:81109-81124. doi:  10.18632/oncotarget.20154
    [22] Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States[J]. JAMA Oncol, 2016, 2:1295-1302. doi:  10.1001/jamaoncol.2016.1025
    [23] 徐颖, 林燕, 王常珺, 等.共识与争议:绝经激素治疗与乳腺癌发病风险[J].协和医学杂志, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc

    Xu Y, Lin Y, Wang CJ, et al. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Med J PUMCH, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc
    [24] Saxena T, Lee E, Henderson KD, et al.Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19:2366-2378. doi:  10.1158/1055-9965.EPI-10-0162
    [25] Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk?[J]. Eur J Cancer, 2017, 84:60-68. doi:  10.1016/j.ejca.2017.07.012
    [26] Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study[J].Lancet, 2003, 362: 419-427. doi:  10.1016/S0140-6736(03)14065-2
    [27] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol 2014, 15:e279-e289. doi:  10.1016/S1470-2045(13)70567-9
    [28] LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a random-ized controlled trial[J]. JAMA, 2011, 305:1305-1314. doi:  10.1001/jama.2011.382
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (231) PDF downloads(46) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return